

FOR FURTHER INFORMATION CONTACT:

Patrick W. McDonough, Executive Director of the Joint Board for the Enrollment of Actuaries, 202-622-8225.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Advisory Committee on Actuarial Examinations will meet in the Internal Revenue Service Building, 1111 Constitution Avenue, NW., Washington, DC on Monday, June 29, 2009, from 9 a.m. to 5 p.m., and Tuesday, June 30, 2009, from 8:30 a.m. to 5 p.m.

The purpose of the meeting is to discuss topics and questions which may be recommended for inclusion on future Joint Board examinations in actuarial mathematics and methodology referred to in 29 U.S.C. 1242(a)(1)(B) and to review the May 2009 Basic (EA-1) and Pension (EA-2B) Joint Board Examinations in order to make recommendations relative thereto, including the minimum acceptable pass score. Topics for inclusion on the syllabus for the Joint Board's examination program for the November 2009 Pension (EA-2A) Examination will be discussed.

A determination has been made as required by section 10(d) of the Federal Advisory Committee Act, 5 U.S.C. App., that the portions of the meeting dealing with the discussion of questions that may appear on the Joint Board's examinations and the review of the May 2009 Joint Board examinations fall within the exceptions to the open meeting requirement set forth in 5 U.S.C. 552b(c)(9)(B), and that the public interest requires that such portions be closed to public participation.

The portion of the meeting dealing with the discussion of the other topics will commence at 1 p.m. on June 29 and will continue for as long as necessary to complete the discussion, but not beyond 3 p.m. Time permitting, after the close of this discussion by Committee members, interested persons may make statements germane to this subject. Persons wishing to make oral statements must notify the Executive Director in writing prior to the meeting in order to aid in scheduling the time available and must submit the written text, or at a minimum, an outline of comments they propose to make orally. Such comments will be limited to 10 minutes in length. All other persons planning to attend the public session must also notify the Executive Director in writing to obtain building entry. Notifications of intent to make an oral statement or to attend must be faxed, no later than June 19, 2009, to 202-622-8300, Attn: Executive Director. Any interested person also may file a written statement for

consideration by the Joint Board and the Committee by sending it to the Executive Director: Joint Board for the Enrollment of Actuaries, c/o Internal Revenue Service, Attn: Executive Director SE:OPR, Room 7238, 1111 Constitution Avenue, NW., Washington, DC 20224.

Dated: May 26, 2009.

Patrick W. McDonough,

Executive Director, Joint Board for the Enrollment of Actuaries.

[FR Doc. E9-13517 Filed 6-8-09; 8:45 am]

BILLING CODE 4830-01-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

This is notice that on January 28, 2009, Stepan Company, Natural Products Department, 100 W. Hunter Avenue, Maywood, New Jersey 07607, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of Coca Leaves (9040), a basic class of controlled substance listed in schedule II.

The company plans to import the listed controlled substance for the manufacture of a bulk controlled substance for distribution to its customer.

No comments, objections, or requests for any hearings will be accepted on any application for registration or re-registration to import coca leaves. As explained in the Correction to Notice of Application pertaining to Rhodes Technologies, 72 FR 3417 (2007), comments and requests for hearings on applications to import narcotic raw material are not appropriate.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedule I or II, which fall under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive,

Springfield, VA 22152; and must be filed no later than July 9, 2009.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975 (40 FR 43745), all applicants for registration to import a basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: June 3, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E9-13353 Filed 6-8-09; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Title 21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on March 18, 2009, Research Triangle Institute, Kenneth H. Davis Jr., Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
1-(1-Phenylcyclohexyl)pyrrolidine (7458).	I
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470).	I
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine (7473).	I

Drug	Schedule	Drug	Schedule	Drug	Schedule
1-Methyl-4-phenyl-4-propionoxypiperidine (9661).	I	Dimenoxadol (9617)	I	Thebacon (9315)	I
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (9663).	I	Dimepheptanol (9618)	I	Thiofentanyl (9835)	I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348).	I	Dimethylthiambutene (9619)	I	Tilidine (9750)	I
2,5-Dimethoxy-4-ethylamphetamine (7399).	I	Dimethyltryptamine (7435)	I	Trimeperidine (9646)	I
2,5-Dimethoxyamphetamine (7396).	I	Dioxaphetyl butyrate (9621)	I	Thiofentanyl (9835)	I
3,4,5-Trimethoxyamphetamine (7390).	I	Dipipanone (9622)	I	1-Phenylcyclohexylamine (7460)	II
3,4-Methylenedioxyamphetamine (7400).	I	Drotebanol (9335)	I	1-	II
3,4-Methylenedioxy-methamphetamine (7405).	I	Ethylmethylthiambutene (9623)	I	Piperidinocyclohexanecarbonitrile (8603).	
3,4-Methylenedioxy-N-ethylamphetamine (7404).	I	Etonitazene (9624)	I	Alfentanil (9737)	II
3-Methylfentanyl (9813)	I	Etorphine except HCl (9056)	I	Alphaprodine (9010)	II
3-Methylthiofentanyl (9833)	I	Etomidate (9625)	I	Amobarbital (2125)	II
4-Bromo-2,5-dimethoxyamphetamine (7391).	I	Fenethylamine (1503)	I	Amphetamine (1100)	II
4-Bromo-2,5-dimethoxyphenethylamine (7392).	I	Furethidine (9626)	I	Anileridine (9020)	II
4-Methyl-2,5-dimethoxyamphetamine (7395).	I	Gamma Hydroxybutyric Acid (2010).	I	Bezitramide (9800)	II
4-Methylaminorex (cis isomer) (1590).	I	Heroin (9200)	I	Carfentanil (9743)	II
4-Methoxyamphetamine (7411) ...	I	Hydromorphanol (9301)	I	Coca Leaves (9040)	II
5-Methoxy-3,4-methylenedioxyamphetamine (7401).	I	Hydroxypethidine (9627)	I	Cocaine (9041)	II
5-Methoxy-N,N-diisopropyltryptamine (7439).	I	Ibogaine (7260)	I	Codeine (9050)	II
Acetorphan (9319)	I	Ketobemidone (9628)	I	Dextropropoxyphene, bulk (non-dosage forms) (9273).	II
Acetyl-alpha-methylfentanyl (9815).	I	Levomoramide (9629)	I	Dihydrocodeine (9120)	II
Acetyldihydrocodeine (9051)	I	Levophenacetylmorphan (9631)	I	Dihydroetorphine (9334)	II
Acetylmethadol (9601)	I	Lysergic acid diethylamide (7315)	I	Diphenoxylate (9170)	II
Allylprodine (9602)	I	Marihuana (7360)	I	Ethylmorphine (9190)	II
Alphacetylmethadol except levo-alphacetylmethadol (9603).	I	Mecloqualone (2572)	I	Etorphine Hcl (9059)	II
Alpha-ethyltryptamine (7249)	I	Mescaline (7381)	I	Fentanyl (9801)	II
Alphameprodine (9604)	I	Methaqualone (2565)	I	Glutethimide (2550)	II
Alphamethadol (9605)	I	Methcathinone (1237)	I	Hydrocodone (9193)	II
Alpha-methylfentanyl (9814)	I	Methyl-desorphan (9302)	I	Hydromorphone (9150)	II
Alpha-methylthiofentanyl (9832) ...	I	Methyldihydromorphan (9304)	I	Isomethadone (9226)	II
Alpha-methyltryptamine (7432)	I	Morpheridine (9632)	I	Levo-alphaacetylmethadol (9648) ..	II
Aminorex (1585)	I	Morphine methylbromide (9305) ..	I	Levomethorphan (9210)	II
Benzethidine (9606)	I	Morphine methylsulfonate (9306)	I	Levorphanol (9220)	II
Benzylmorphine (9052)	I	Morphine-N-Oxide (9307)	I	Lisdexamfetamine (1205)	II
Betacetylmethadol (9607)	I	Myrophine (9308)	I	Meperidine (9230)	II
Beta-hydroxy-3-methylfentanyl (9831).	I	N,N-Dimethylamphetamine (1480)	I	Meperidine intermediate-A (9232)	II
Beta-hydroxyfentanyl (9830)	I	N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (9834).	I	Meperidine intermediate-B (9233)	II
Betameprodine (9608)	I	N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (9818).	I	Meperidine intermediate-C (9234)	II
Betamethadol (9609)	I	N-Benzylpiperazine (7493)	I	Metazocine (9240)	II
Betaprodine (9611)	I	N-Ethyl-3-piperidyl benzilate (7482).	I	Methadone (9250)	II
Bufotenine (7433)	I	N-Ethylamphetamine (1475)	I	Methadone intermediate (9254) ...	II
Cathinone (1235)	I	N-Ethyl-1-phenylcyclohexylamine (7455).	I	Methamphetamine (1105)	II
Clonitazene (9612)	I	N-Hydroxy-3,4-methylenedioxyamphetamine (7402).	I	Methylphenidate (1724)	II
Codeine methylbromide (9070)	I	Nicocodine (9309)	I	Metopon (9260)	II
Codeine-N-Oxide (9053)	I	Nicomorphine (9312)	I	Moramide intermediate (9802)	II
Cyprenorphine (9054)	I	N-Methyl-3-piperidyl benzilate (7484).	I	Morphine (9300)	II
Desomorphine (9055)	I	Noracymethadol (9633)	I	Nabilone (7379)	II
Dextromoramide (9613)	I	Norlevorphanol (9634)	I	Opium, raw (9600)	II
Diampromide (9615)	I	Normethadone (9635)	I	Opium extracts (9610)	II
Diethylthiambutene (9616)	I	Normorphine (9313)	I	Opium fluid extract (9620)	II
Diethyltryptamine (7434)	I	Norpipanone (9636)	I	Opium tincture (9630)	II
Difenoxin (9168)	I	Para-Fluorofentanyl (9812)	I	Opium, granulated (9640)	II
Dihydromorphan (9145)	I	Parahexyl (7374)	I	Oxycodone (9143)	II
		Peyote (7415)	I	Oxymorphone (9652)	II
		Phenadoxone (9637)	I	Pentobarbital (2270)	II
		Phenampromide (9638)	I	Phenazocine (9715)	II
		Phenomorphan (9647)	I	Phencyclidine (7471)	II
		Phenoperidine (9641)	I	Phenmetrazine (1631)	II
		Pholcodine (9314)	I	Phenylacetone (8501)	II
		Piritramide (9642)	I	Piminodine (9730)	II
		Proheptazine (9643)	I	Powdered opium (9639)	II
		Properidine (9644)	I	Racemethorphan (9732)	II
		Propiram (9649)	I	Racemorphan (9733)	II
		Psilocybin (7437)	I	Remifentanyl (9739)	II
		Psilocyn (7438)	I	Secobarbital (2315)	II
		Racemoramide (9645)	I	Sufentanil (9740)	II
		Tetrahydrocannabinols (7370)	I	Thebaine (9333)	II

The company plans to import small quantities of the listed controlled substances for the National Institute on Drug Abuse (NIDA) for research activities.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than July 9, 2009.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substances in schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: June 3, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E9–13357 Filed 6–8–09; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2), authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Title 21, Code of Federal Regulations (CFR), 1301.34(a), this is notice that on January 5, 2009, Mylan Pharmaceuticals Inc., 781 Chestnut Ridge Road, Morgantown, West Virginia 26505, made application by letter to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule II:

Drug	Schedule
Methylphenidate (1724)	II
Fentanyl (9801)	II

The company plans to import the listed controlled substances for analytical research and clinical trials.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than July 9, 2009.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substance in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: June 3, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E9–13360 Filed 6–8–09; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2), authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Title 21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on January 5, 2009, Mylan Technologies Inc., 110 Lake Street, Saint Albans, Vermont 05478, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule II:

Drug	Schedule
Methylphenidate (1724)	II
Fentanyl (9801)	II

The company plans to import the listed controlled substances for analytical research and clinical trials.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than July 9, 2009.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substance in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements